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| INTRODUC TI ON
After extensive research for more than a century, immunotherapy is now the fourth standard treatment after surgery, chemotherapy, and radiotherapy for various types of malignancy.
1 Despite the great success of immune checkpoint inhibitors (ICIs) as monotherapy, more than half of patients are still not responsive to these agents, even those with tumors that are approved for these treatments, including melanoma, renal cell carcinoma, and non-small-cell lung carcinoma.
Substantial numbers of patients are not eligible for this therapy because the type of malignancy is not sensitive to ICIs. Furthermore, ICIs are not specific for tumor cells, so serious immune-related adverse events often result in discontinuation of treatment. Five years after the approval of ICIs, we are now at a crossroads in terms of further improvement in immunotherapy for cancer.
We have sought and identified many cancer-specific and sarcoma-specific antigens that are promising candidates for tumorspecific immunotherapy. 2 Immunization with HLA-A24-restricted survivin 2B 80-88 (SVN-2B) peptide, which is derived from a splice variant of survivin, a member of the inhibitor of apoptosis protein family, was observed to induce a strong immune reaction in in vitro studies. 3, 4 Furthermore, encouraging results were obtained in phase I clinical studies of the use of this peptide vaccine in pancreatic, colorectal, and urothelial carcinoma. [5] [6] [7] Importantly, no severe adverse effects occurred after administration of the SVN-2B peptide vaccine. There is also a noteworthy report of a patient with advanced pancreatic carcinoma who received the SVN-2B peptide vaccine as sole treatment more than 10 years ago and remains alive. Recently, we undertook an SVN-2B vaccine-based phase II randomized clinical trial targeting pancreatic carcinoma that was unresectable and refractory to existing therapies. The SVN-2B peptide vaccine induces proliferation and activation of SVN-2B peptide-specific CTLs.
However, the vaccine did not improve progression-free survival, as reported by Shima et al. in this issue. These lesions were found in only inoculated cases, indicating that tumor-specific peptide vaccination could be an upcoming partner of ICI treatment for malignancies.
| MATERIAL S AND ME THODS

| Patients and specimens
A total of 83 patients with unresectable and refractory pancreatic carcinoma were enrolled in the phase II clinical trial (clinical trial registration number: UMIN 000012146). All patients were found to have the HLA-A24 allele and expression of HLA class I and survivin on examination of biopsy specimens. The protocol for this trial is described in detail in the parallel publication by Shima et al. 8 Autopsies were carried out in 7 of these patients; the vaccination schedule for each of these patients is shown in Figure 1A . Five patients who had not participated in the clinical trial and 1 who had been treated with nivolumab were included as the control group. The clinicopathological factors analyzed in this study are summarized in Table 1 . Written informed consent was obtained from each patient and the study was conducted according to the guidelines of the Declaration of Helsinki.
There was no significant difference in the male to female patient immune-related molecules was analyzed by immunohistochemical staining. Cytotoxic T lymphocytes were analyzed by tetramer staining and enzyme-linked immunospot assay. Histological analysis revealed dense infiltration of CD8 + T cells in some lesions in patients who had received the SVN-2B peptide vaccine. A high rate of programmed cell death ligand 1 expression in cancer cells was observed in these cases, indicating that CTLs were induced by SVN-2B peptide vaccination and had infiltrated the lesions. The lack of a significant antitumor effect was most likely attributable to the expression of immune checkpoint molecules. These findings suggest that the combination of a tumor-specific peptide vaccine and an ICI might be a promising approach to the treatment of pancreatic carcinoma in the future.
K E Y W O R D S
autopsy, immunohistochemistry, pancreatic carcinoma, peptide vaccine, survivin ratio or in the mean age (with vaccination, 59.9 ± 17.0 years; without vaccination, 68.3 ± 5.6 years, P = .27).
| Immunohistochemical staining
The tumor tissues were fixed in 10% buffered formalin and embed- 
| Cytotoxic T lymphocyte analysis
Peptide-specific CTLs were detected using a tetramer binding assay.
We used phycoerythrin-labeled HLA-A*2402/SVN-2B peptide 
| Statistical analysis
Data are shown as the mean ± SD. Student's t test and Pearson's correlation coefficient were used for all analyses as appropriate. All statistical analyses were carried out using GraphPad Prism software (version 6.0 for Windows; GraphPad Software, La Jolla, CA, USA). P values <.05 were considered statistically significant.
| RE SULTS
| Summary of clinical trial and autopsy study
A detailed analysis and discussion of the clinical trial are described in the parallel publication by Shima et al. 8 Briefly, treatment with SVN-2B peptide with or without IFNβ inoculation did not improve progression-free survival, although some immunological effect was noted, namely, increased numbers of IFNγ-producing and/or survivin 2B 80-88-specific CTLs in peripheral blood. All patients in whom an autopsy was carried out, including the controls, had died as a result of their cancer, and the primary or metastasized lesion was sampled postmortem. Histopathologically, we found the tumors varied from well to poorly differentiated adenocarcinoma and even included anaplastic carcinoma. Necrosis was occasionally observed, especially in the center of the lesions. However, the majority of tumor cells
were viable in all cases.
| Survivin and HLA class I expression in tumors
Before enrolling patients in the clinical trial, we confirmed that 
Abbreviations: F, female; FOLFIRINOX, leucovorin + fluorouracil + irinotecan + oxaliplatin; GEM, gemcitabine; HIT, heavy ion radiotherapy; M, male; MTS, maximum tumor shrinkage; nabPTX, nanoparticle albumin-bound paclitaxel; OS, overall survival; PBT, proton beam therapy; PFS, progression-free survival; S-1, tegafur/gimeracil/oteracil potassium.
TA B L E 1 Clinicopathological factors in this series of autopsy cases ( Figure 1D ), indicating that the distribution of CD8 + cells was heterogenous. Therefore, we counted the CTLs that had infiltrated the tumor and interstitial tissue separately to distinguish these 2 patterns ( Figure 1E ) and found a correlation between CD8 + cells in tumor tissue and those in interstitial tissue (r = 0.45, P = .014; Figure S1A ).
In the majority of the lesions, infiltration of CD8 or activation of these cells. 10 Therefore, we investigated Treg-positive infiltration in the lesions using FOXP3 staining as a surrogate marker ( Figure 2D ). Most FOXP3 + cells were found only in the interstitial tissue. Furthermore, the numbers of lymphocytes that expressed FOXP3 were relatively small, as reported previously. 11 In our study, there was no significant difference in infiltration of FOXP3 + cells between the patients who did and did not receive the vaccination ( Figure S4A ). The ratio of CD8 + cells and FOXP3 + cells in tumors was higher in the vaccination group than in the control group (P = .012; Figure S4B ). However, the ratio of interstitial CD8 + cells to FOXP3 + cells was not significantly different between the groups ( Figure S4C ). 
F I G U R E 3 In situ investigation of infiltration of CD8
| Correlation between PD-L1 expression and CD8 + and PD-1 + cell infiltration
Detecting PD-L1 expression by immunohistochemistry using formalin-fixed, paraffin-embedded specimens is now recognized as a biomarker of the efficacy of treatment with PD-1-blocking
ICIs in some types of malignancy. 12, 13 To investigate the potential value of combination therapy consisting of tumor-specific peptide vaccine and ICI, we examined PD-L1 expression in the tumor specimens ( Figure 2E ). Although the lesions in patients who had received the SVN-2B peptide vaccine tended to show higher PD-L1 expression than those in patients who had not, the difference was not statistically significant ( Figure S5 ). As reported for CD8, some lesions showed abundant expression of PD-L1 and others did not ( Figure S6 ). Interestingly, there was a significant correlation between the level of PD-L1 expression and the numbers of CD8 + and PD-1 + cells in each lesion (r = 0.83, P < .001 and r = 0.54, P = .001, respectively; Figure 3G ,H).
| Case presentations
Two cases are presented to demonstrate the significant immune reactions that occurred in peripheral blood and local tumor tissue.
The first case (Table 1, She was entered into our clinical trial and initially assigned to the group that received SVN-2B vaccination but not IFNβ ( Figure 1A ).
She developed progressive disease, so was then given IFNβ in addition to the SVN-2B peptide vaccine but died 115 days after the first vaccination.
When the immunological effect of the first vaccination was evaluated at 8 weeks (before addition of IFNβ to her treatment), the numbers of IFNγ-producing and peptide-specific CD8 + T cells were significantly increased in peripheral blood ( Figure 4A, B) . The gross appearance of the cut surface of a hepatic lesion obtained from this patient is shown in Figure 4C . Microscopically, the tumor showed undifferentiated morphology and high expression of PD-L1 with abundant infiltration of CD8 + cells ( Figure 4D ).
The second case (Table 1 , patient 7) was a 65-year-old woman who underwent surgery after S-1-based neoadjuvant chemotherapy.
The patient developed local recurrence that was treated with proton beam therapy. She was subsequently treated with GEM + nanoparticle albumin-bound paclitaxel and S-1 + GEM. She then developed progressive disease, so she was entered into our clinical trial and assigned to receive SVN-2B + IFNβ vaccination ( Figure 1A) .
Unfortunately, the disease progressed and she died 76 days after the first vaccination.
The immunological findings in the peripheral blood of this patient at 8 weeks after the first vaccination were very similar to those in case 1, as were the immunopathological findings ( Figure 4E,F,H) . Figure 4G depicts the gross appearance of a lesion in the patient's liver that showed cystic change suggestive of central necrosis.
Viable carcinoma with high PD-L1 expression and harboring a larger number of CD8 + cells was observed at the margin, which was the area sampled for histological analysis. In this investigation, almost all tumor cells expressed HLA class I antigen, which is a prerequisite for CTL-based immunotherapy in cancer. However, we had a few cases in which we immunohistochemically analyzed survivin, which was a target in this trial. All the tumor cells that were positive for survivin were detected using the same immunohistochemistry protocol in biopsy specimens, suggesting immune escape through loss of the target. From the biological point of view, survivin is a member of the inhibitor of apoptosis protein family, which inhibits apoptosis-related caspase activity.
| D ISCUSS I ON
26
Therefore, given the amount of research demonstrating the functional importance of survivin in the survival of tumor cells, we consider that survivin expression might not have been appropriately detected by immunohistochemistry in our study, probably because of the altered fixation conditions brought about by use of formalin in autopsy specimens, which might have affected staining for survivin.
Other researchers reported that only 16.7% of control tumors were positive for survivin whereas survivin was detected in more than 75% of pancreatic adenocarcinomas. 27, 28 A sophisticated fixation procedure or antisurvivin mAb would be needed.
In conclusion, vaccination with survivin 2B 80-88 peptide, a tumor-specific antigen, can be a potent immunological manipulation for pancreatic carcinoma, which is a cancer with relatively low amounts of immunogenic neoantigen. Combined use of this cancer vaccine and ICI therapy to inhibit the PD-1 axis might be worth attempting in expanded indications and could have less severe adverse effects. However, more than half of the vaccinated patients did not
show infiltration of CTLs into the tumor at autopsy, indicating that some of the mechanisms that promote cancer immunity are still unknown. Comprehensive understanding and a combinational approach should lead us to the next generation of cancer immunotherapy, which hopefully will prove to be highly effective as standard therapy. 
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